Earnings Call Summary | Vaxart(VXRT.US) Q4 2023 Earnings Conference
Earnings Call Summary | Vaxart(VXRT.US) Q4 2023 Earnings Conference
The following is a summary of the Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript:
以下是Vaxart, Inc.（VXRT）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Vaxart reported a revenue of $7.4 million in 2023, an increase compared to $0.1 million in 2022, primarily due to the Bill & Melinda Gates Foundation grant and increased sales of Inavir in Japan.
The company ended 2023 with cash, cash equivalents, and investments totaling $39.7 million, and raised an additional $15 million in net proceeds in early 2024, estimating a cash runway into the fourth quarter of 2024.
Vaxart received a $9.27 million contract from BARDA to prepare for a 10,000-subject Phase 2b clinical trial of their oral pill XBB COVID-19 vaccine candidate, potentially beginning in Q2 2024.
Vaxart報告稱，2023年收入爲740萬美元，與2022年的10萬美元相比有所增加，這主要是由於比爾和梅琳達·蓋茨基金會的撥款以及Inavir在日本的銷售額增加。
該公司在2023年底的現金、現金等價物和投資總額爲3,970萬美元，並於2024年初又籌集了1500萬美元的淨收益，估計到2024年第四季度的現金流將持續到2024年第四季度。
Vaxart從BARDA獲得了一份價值927萬美元的合同，爲其口服藥XBB COVID-19 候選疫苗的10,000名受試者的2b期臨床試驗做準備，該試驗可能在2024年第二季度開始。
Business Progress:
業務進展：
Vaxart saw growth in their norovirus program and completed two phase 2 studies in 2023.
The company established proof of concept in two challenge studies for respiratory and gastrointestinal viruses.
Vaxart progressed with their COVID-19 vaccine program, aiming to produce more effective vaccines against various strains of the virus, with the support of a recent BARDA contract award.
The company has planned a meeting with the FDA in 2024 over their Phase 2b dose confirmation study and believes they have the most advanced norovirus vaccine candidate in clinical development.
The company has appointed a new President and CEO, Steve Lo.
Vaxart的諾如病毒項目有所增長，並於2023年完成了兩項2期研究。
該公司在兩項呼吸道和胃腸道病毒挑戰研究中建立了概念驗證。
Vaxart 在 BARDA 最近授予的合同支持下，其 COVID-19 疫苗計劃取得了進展，旨在生產針對各種病毒株的更有效的疫苗。
該公司計劃在2024年與美國食品藥品管理局就其2b期劑量確認研究舉行會議，並認爲他們擁有臨床開發中最先進的諾如病毒候選疫苗。
該公司已任命新的總裁兼首席執行官史蒂夫·羅。
More details: Vaxart IR
更多詳情： Vaxart 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。